BIOGEN INC. - COMMON STOCK

Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review

22 Dec 2021 07:30:00 By Nasdaq GlobeNewswire

Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease

20 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Update on Regulatory Submission for Aducanumab in the European Union

17 Dec 2021 06:43:58 By Nasdaq GlobeNewswire

Update on the Phase 4 Confirmatory Study of ADUHELM®

16 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience

14 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Update on Regulatory Review of Aducanumab in the European Union

17 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis

16 Nov 2021 09:20:00 By Nasdaq GlobeNewswire

Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development

15 Nov 2021 19:44:06 By Nasdaq GlobeNewswire

Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year

15 Nov 2021 07:30:01 By Nasdaq GlobeNewswire

New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease

11 Nov 2021 17:10:00 By Nasdaq GlobeNewswire